• Zolbetuximab, sold under the brand name Vyloy, is a monoclonal antibody used for the treatment of gastric cancer. It is a claudin 18.2-directed cytolytic...
    11 KB (828 words) - 16:47, 2 November 2024
  • Zokinvy Zoladex zolamine (INN) zolasartan (INN) zolazepam (INN) zolbetuximab (INN) zolbetuximab-clzb zoledronic acid (INN) Zoledronic zolenzepine (INN) zoleprodolol...
    10 KB (573 words) - 05:03, 24 November 2024
  • Thumbnail for Astellas Pharma
    review to Astellas Pharma's biologics licence application (BLA) for Zolbetuximab, a monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the treatment...
    27 KB (2,460 words) - 00:25, 13 September 2024
  • Thumbnail for Uğur Şahin
    his mentor Christoph Huber. Ganymed developed the monoclonal antibody Zolbetuximab, for use against esophageal and gastrointestinal cancer. In 2016, after...
    56 KB (6,118 words) - 17:41, 13 November 2024
  • govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zolbetuximab...
    12 KB (821 words) - 02:57, 12 October 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    (FDA). 21 November 2024. Retrieved 23 November 2024. "Astellas' Vyloy (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer" (Press release)....
    137 KB (4,115 words) - 07:44, 23 November 2024
  • Thumbnail for CLDN18
    [supplied by OMIM] Isoform 2 (Claudin 18.2) is abundant in gastric tumors. Zolbetuximab targets Claudin 18.2 to help treat gastric cancers. GRCh38: Ensembl release...
    5 KB (590 words) - 13:48, 29 September 2024
  • Thumbnail for Özlem Türeci
    class of cancer drugs called ideal monoclonal antibodies and developed zolbetuximab, which is used to treat esophageal and gastric cancer. She was chief...
    42 KB (3,520 words) - 04:23, 21 August 2024
  • govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zolbetuximab...
    12 KB (758 words) - 23:46, 14 March 2024
  • Thumbnail for Naptumomab estafenatox
    Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab...
    4 KB (241 words) - 13:42, 14 July 2024
  • Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab...
    5 KB (368 words) - 15:29, 21 August 2024
  • Margetuximab Mirvetuximab soravtansine Rituximab# Siltuximab Ublituximab Zolbetuximab Humanized Abituzumab§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab...
    3 KB (129 words) - 01:04, 19 July 2023